| References |
[1]. Bicchi C, et, al. Simultaneous determination of six triazolic pesticide residues in apple and pear pulps by liquid chromatography with ultraviolet diode array detection. J AOAC Int. Sep-Oct 2001;84(5):1543-50.
[2]. Mercer EI, et, al. Effect of some sterol-biosynthesis-inhibiting fungicides on the biosynthesis of polyisoprenoid compounds in barley seedings. Steroids. Mar-May 1989;53(3-5):393-412. [3]. Lamb DC, et, al. Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. Chem Biol Interact. 2000 Mar 15;125(3):165-75. |
|---|---|
| Additional Infomation |
Diclofenazole is a type of azole fungicide and a triazole fungicide.
|
| Exact Mass |
327.09
|
|---|---|
| CAS # |
75736-33-3
|
| PubChem CID |
53309
|
| Appearance |
White to off-white solid powder
|
| Density |
1.28 g/cm3
|
| Boiling Point |
484.3ºC at 760 mmHg
|
| Melting Point |
140 - 143ºC
|
| Flash Point |
>100ºC
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
URDNHJIVMYZFRT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H19Cl2N3O/c1-15(2,3)14(21)13(20-9-18-8-19-20)6-10-4-5-11(16)7-12(10)17/h4-5,7-9,13-14,21H,6H2,1-3H3
|
| Chemical Name |
1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pentan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT02346747
Conditions:Ovarian Cancer|Ovarian NeoplasmsLink: https://clinicaltrials.gov/ct2/show/NCT03842865
Conditions:Solid Tumor|Ewing Sarcoma|Ewing's Tumor Metastatic|Ewing's Sarcoma Metastatic|Advanced Gynecological Cancers|Ovarian Cancer|Cervical Cancer|Uterine CancerLink: https://clinicaltrials.gov/ct2/show/NCT05855187
Conditions:Healthy
Title:A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Status:Terminated
updateDate:2023-04-26
Ctid:NCT03495921
Link: https://clinicaltrials.gov/ct2/show/NCT03495921
Conditions:Ewing Sarcoma|Ewing Family of Tumors|Ewing's Tumor Metastatic|Ewing's Sarcoma Metastatic|Ewing's Tumor Recurrent|Rare Diseases|Sarcoma|Neoplasms, Connective and Soft Tissue|Neoplasms by Histologic Type|Neoplasms, Bone Tissue|Neoplasms, Connective Tissue|Sarcoma, Ewing|NeoplasmsLink: https://clinicaltrials.gov/ct2/show/NCT03073525
Conditions:Advanced Gynecological Cancers|Ovarian Cancer|Cervical Cancer|Uterine CancerLink: https://clinicaltrials.gov/ct2/show/NCT02511132
Conditions:Ewing's SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT02725489
Conditions:Breast Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Uterine Cancer|Cervical Cancer|Endometrial CancerLink: https://clinicaltrials.gov/ct2/show/NCT02574533
Conditions:Melanoma Recurrent|Malignant Melanoma|MelanomaLink: https://clinicaltrials.gov/ct2/show/NCT01638403
Conditions:Treatment of Excessive Daytime Sleepiness in NarcolepsyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
